A full portfolio of blood-based and CSF tests, including QUEST AD-Detect™, which uses noninvasive tests for a range of biomarkers that can help provide better understanding of a patient’s potential risk for dementia or Alzheimer’s disease.
Make advanced neurology testing more accessible and actionable
Neurological diseases are complex. Managing lab testing for them shouldn’t be. In most cases, early detection and prompt therapy can improve patient outcomes if testing can be easily available. Quest offers a comprehensive neurological testing portfolio, including blood and Comprehensive Cerebrospinal Fluid (CSF) testing methods, so you can provide the answers and care your patients deserve.
Click below for featured tests from our portfolio of over 400 neurological tests.
Expanded offerings for several autoimmune neurological disorders, including:
- Paraneoplastic neurological syndromes (PNS)
- Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG) antibody disease
- Autoimmune encephalitis and epilepsy
- Myasthenia gravis
- Multiple sclerosis
- Peripheral neuropathy
Testing for myasthenia gravis, paraneoplastic syndromes, autoimmune encephalitis, neuromyelitis optica, peripheral neuropathy, and multiple sclerosis. Our expansive test menu includes over 40 antibodies and utilizes gold-standard methodologies, such as CBA, RIA, and line blot.1
AAP guideline-based chromosomal microarray analysis (CMA)2, which has the highest diagnostic yield of any single test for children that is currently available to clinicians.
The insights your clinicians need to manage IEM-derived challenges with a comprehensive genetic test menu and on-demand expertise from genetic counselors.
A full range of stroke testing that can help inform care plans and treatment monitoring.
Eliminating the unknowns
No matter where patients fall on the diagnostic journey, our complete portfolio of molecular, biochemical, neuroimmunological, and cytogenetic testing can help healthcare providers find the resources to move forward with clarity and confidence.
References
1. Stocker W, Probst C, Teegen B, et al. Multiparameter autoantibody screening in the diagnosis of neurological autoimmune diseases. Paper presented at: 1st Congress of the European Academy of Neurology (EAN); June 2015; Berlin, Germany.
2. Sathirapongsasuti JF, Lee H, Horst BA, et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics. 2011;27(19):2648-2654. doi:10.1093/bioinformatics/btr462
Take your lab to the next level
See how Quest can enhance your laboratory supply chain.
Lab management
Lab testing by specialty
Browse test directory
Not sure what test you're looking for, or just want to see everything we can do?
- Site map
- Privacy Notices
- Terms
- Contact us
- Language assistance / non-discrimination
- Asistencia de idiomas / Aviso de no discriminación
- 語言協助 / 不歧視通知
- Accessibility
-
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.